Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol-enhanced MRA for Pulmonary Embolism
NCT03173066Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2018
- Primary completion
- May 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ferumoxytol in pulmonary embolism (PE), sponsored by Brigham and Women's Hospital. Primary endpoint: Pulmonary embolus at 1 year. Started Sep 2018; status: completed.
02
Drugs
ferumoxytol
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03173066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173066.